Corcept Therapeutics Incorporated
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Corcept Therapeutics Incorporated's yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Self-Funding Ratio: Over the last 3 years its own operating cash covered its investment spending (capex) 185.2 times. Higher than almost all Healthcare companies in United States.
- Debt Due Cover Ratio: Debt due within a year is covered 131.0 times by its yearly operating cash. Higher than 98% of Healthcare companies in United States.
- Cash Locked Ratio: For every $100 of sales, $4 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $10 tied up three years earlier. Less money tied up than 88% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
$135Over the last 3 years, every $100 of reported profit came with $135 of operating cash.
Lower than 61% of Healthcare companies in United States.
Self-Funding Ratio
100×+Over the last 3 years its own operating cash covered its investment spending (capex) 185.2 times.
Higher than almost all Healthcare companies in United States.
Cash Locked Ratio
$4For every $100 of sales, $4 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $10 tied up three years earlier.
Less money tied up than 88% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
3/3 · 2/3Sales grew in 3 of the last 3 years; profit grew in 2 of 3.
Steadier than 85% of Healthcare companies in United States.
Growth Efficiency Ratio
−$0Sales grew 89% in 3 years, but profit fell: $0 less profit per $100 of extra sales.
Lower than 68% of Healthcare companies in United States.
Asset Productivity Ratio
+89% / +43%In 3 years sales changed by +89% while total assets changed by +43%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
131.0×Debt due within a year is covered 131.0 times by its yearly operating cash.
Higher than 98% of Healthcare companies in United States.
Cash Cushion Ratio
+3%Cash, after subtracting all debt, equals 3% of its market value (net cash).
Lower than 62% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Corcept Therapeutics Incorporated owes $0.21 for every $1 it owns. Net profit fell 29% in the year to Dec 2025, and shrank 1% a year on average over 3 years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
238.9Investors pay $238.9 for every $1 of Corcept Therapeutics Incorporated's yearly profit, higher than 96% of Healthcare companies in United States.
P/B ratio
16.46The share price is 16.46 times Corcept Therapeutics Incorporated's book value per share, higher than 92% of Healthcare companies in United States.
Market cap
$11.6 BThe total market value of all of Corcept Therapeutics Incorporated's shares at today's price (share price × number of shares), larger than 91% of Healthcare companies in United States. PosiCap size class: Tito Cap.
Net worth (book value)
$706 MWhat Corcept Therapeutics Incorporated would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$6.53Net worth divided by the number of shares. The share price of $107.50 is 16.5 times this, which is the P/B above.
Return on equity (ROE)
8.2%Corcept Therapeutics Incorporated earned 8.2% on its shareholders' money over the last year, higher than 82% of Healthcare companies in United States.
Owes vs Owns
0.21×Corcept Therapeutics Incorporated owes $0.21 for every $1 it owns (low), lower than 71% of Healthcare companies in United States.
Dividend yield
NoneCorcept Therapeutics Incorporated does not currently pay a dividend.
Revenue growth
+13%Revenue rose 13% in the year to Dec 2025, and grew 24% a year on average over 3 years.
Profit growth
-29%Net profit fell 29% in the year to Dec 2025, and shrank 1% a year on average over 3 years.
Profit margin
13.1%Corcept Therapeutics Incorporated keeps $13 of every $100 of revenue as net profit.
Cash quality
1.4×Cash from Corcept Therapeutics Incorporated's business was 1.4× its reported profit in the year to Dec 2025 — its profit turned into cash.
Cash vs debt
Net cashCorcept Therapeutics Incorporated held $366 M more cash than debt (net cash) at Dec 2025.
Questions
What is Corcept Therapeutics Incorporated's P/E ratio?
Investors pay $238.9 for every $1 of Corcept Therapeutics Incorporated's yearly profit, higher than 96% of Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Corcept Therapeutics Incorporated: $11.6 B ÷ $706 M (30 Jun 2026) = 16.5.
What is Corcept Therapeutics Incorporated's return on equity?
Corcept Therapeutics Incorporated earned 8.2% on its shareholders' money over the last year, higher than 82% of Healthcare companies in United States.
How much does Corcept Therapeutics Incorporated owe compared with what it owns?
Corcept Therapeutics Incorporated owes $0.21 for every $1 it owns (low), lower than 71% of Healthcare companies in United States.
Does Corcept Therapeutics Incorporated pay a dividend?
No. Corcept Therapeutics Incorporated does not currently pay a dividend.
Is Corcept Therapeutics Incorporated's revenue growing?
Revenue rose 13% in the year to Dec 2025, and grew 24% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.